Abstract
Multiple sclerosis (MS) is a common inflammatory and demyelinating disease of the central nervous system (CNS), which causes progressive neurological disability. The disease is characterised pathologically by destruction of the myelin sheaths, which surround nerve fibres in the CNS. It is believed that this tissue damage in the brain and spinal cord of MS patients is caused by an inflammatory response that is initiated when autoreactive T cells, specific for myelin antigens, cross the blood-brain barrier and detect their antigen within the CNS. As a result, most therapies to date have been immunosuppressive and/or anti-inflammatory in nature, targeting the processes involved in activation and migration of leukocytes and promotion of the immune response. Over the last decade, a family of chemotactic cytokines called chemokines, have been found to be involved in the trafficking of leukocytes in both the normal and pathological states. The expression of these chemokines and their receptors is increased during the acute phase of MS and also in the animal model of MS, experimental autoimmune encephalomyelitis (EAE). As a result, these chemokines have become an emerging focus for research into novel therapeutics for EAE and ultimatel...Continue Reading
Citations
Feb 3, 2007·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Juliana Croitoru-LamouryBruce J Brew
May 10, 2008·Journal of Veterinary Internal Medicine·T M FanL D Garrett
Aug 2, 2008·PPAR Research·John J BrightSharmistha Chakraborty
Aug 14, 2012·Journal of Neuroinflammation·Jeffrey H MillsMargaret S Bynoe
May 14, 2010·PloS One·Kaushal S GandhiJonathan W Arthur
Nov 8, 2011·CNS Drugs·Elizabeth R Comini-FrotaEduardo A Donadi
Jan 21, 2011·Scandinavian Journal of Rheumatology·H Van NguyenD Wakefield
Apr 23, 2013·Journal of Neuroimmunology·Adeola I OyebamijiShalina S Ousman
Feb 24, 2009·Journal of Neuroimmunology·E BriniG Martino
Nov 11, 2008·Molecular and Cellular Endocrinology·Malgorzata Burek, Carola Y Förster
Aug 19, 2008·Journal of the Neurological Sciences·Isabell HamannCarmen Infante-Duarte
Sep 9, 2008·Experimental and Molecular Pathology·Yangtai GuanGuang-Xian Zhang
Jul 8, 2008·International Immunopharmacology·Marcio L De PaulaAna P Ferreira
Sep 10, 2005·Journal of Neurochemistry·Romain Daniel GosselinStéphane Melik-Parsadaniantz
Sep 15, 2006·Scandinavian Journal of Immunology·A PahujaD G Alleva
Jan 6, 2010·British Journal of Pharmacology·Jia NiJian-Ping Zuo
Oct 3, 2006·Current Opinion in Immunology·Natalia M Rebenko-MollRichard M Ransohoff
Aug 4, 2006·Journal of Neuroimmunology·Christine Silwedel, Carola Förster
Nov 29, 2005·Trends in Pharmacological Sciences·Eroboghene E UboguRichard M Ransohoff
Jan 22, 2008·Journal of Neuroimmunology·Sergey G KremlevGeorge Tuszynski
Oct 29, 2005·Drug Discovery Today·Bert A 't Hart, Kees Heije
Feb 26, 2005·Journal of Neuroinflammation·Ileana BanisorBernadette Kalman
Jan 15, 2015·Journal of the Neurological Sciences·Piotr Iwanowski, Jacek Losy
Aug 24, 2005·Immunopharmacology and Immunotoxicology·Abbas MirshafieySeiji Miyoshi
Mar 14, 2019·Frontiers in Cellular Neuroscience·Luisa F DuartePablo A González